OVERSEA CHINESE BANKING Corp Ltd Takes $983,000 Position in DaVita Inc. (NYSE:DVA)

OVERSEA CHINESE BANKING Corp Ltd purchased a new stake in DaVita Inc. (NYSE:DVA) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 6,373 shares of the company’s stock, valued at approximately $983,000.

A number of other large investors have also added to or reduced their stakes in DVA. Atria Investments Inc grew its position in DaVita by 12.3% during the third quarter. Atria Investments Inc now owns 2,897 shares of the company’s stock worth $475,000 after buying an additional 317 shares in the last quarter. Empowered Funds LLC grew its position in DaVita by 25.6% during the third quarter. Empowered Funds LLC now owns 5,824 shares of the company’s stock worth $955,000 after buying an additional 1,187 shares in the last quarter. Thrivent Financial for Lutherans grew its position in DaVita by 49.4% during the third quarter. Thrivent Financial for Lutherans now owns 8,131 shares of the company’s stock worth $1,333,000 after buying an additional 2,688 shares in the last quarter. Quest Partners LLC acquired a new stake in DaVita during the third quarter worth approximately $669,000. Finally, B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in DaVita during the third quarter worth approximately $923,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Trading Up 0.4 %

NYSE DVA opened at $150.00 on Thursday. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. DaVita Inc. has a twelve month low of $125.64 and a twelve month high of $179.60. The company has a market cap of $12.00 billion, a price-to-earnings ratio of 13.97, a price-to-earnings-growth ratio of 1.07 and a beta of 0.99. The business’s fifty day moving average is $158.73 and its 200 day moving average is $157.55.

DaVita (NYSE:DVA) last released its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. As a group, sell-side analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

DVA has been the topic of a number of analyst reports. Cowen reissued a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on DaVita in a report on Friday, February 21st. Finally, Barclays raised their target price on DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $166.33.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.